MGST3

Across TCGA pan-cancer cohorts, MGST3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MGST3 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MGST3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MGST3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where MGST3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.515	0.950	.001	39	view →
HNSC	DFS	Tertile	III,IV	0.860	0.609	.002	19	view →
LSCC	DFS	Quartile	All	0.480	0.881	.001	17	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
GBM	DFS	Tertile	All	0.848	0.624	.015	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MGST3–CCRCC (DFS)

Open the CCRCC breakdown →